OR WAIT null SECS
August 16, 2022
Zoryve is a next-generation topical PDE4 inhibitor to treat adults and adolescents with plaque psoriasis.
August 01, 2022
Zoryve, the first topical PDE4 inhibitor approved to treat patients with plaque psoriasis, will be available by mid-August.
July 19, 2022
Opzelura is first therapy approved to treat patients with vitiligo, a disease that causes the loss of skin color.
July 11, 2022
Piclidenoson is a first-in-class, A3 adenosine receptor agonist small molecule that inhibits the inflammatory cytokines interleukin 17 and 23.
June 14, 2022
Olumiant is the first systemic therapy available to treat alopecia.
June 08, 2022
Dupixent is the first biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy through adulthood.
June 01, 2022
If approved, Dupixent would be the first and only medicine in the United States specifically indicated to treat prurigo nodularis, or persistent itch with thick skin lesions. The PDUFA target action date for the FDA decision is Sept. 30, 2022.
May 26, 2022
Deficiencies at the contract manufacturing company are, for the second time, holding up approval of VP-102 to treat molluscum contagiosum, a mild skin infection.
May 24, 2022
Vtama is approved to treat adults with mild, moderate, and severe psoriasis. It is expected to be available in the first week of June 2022.
May 18, 2022
Bimekizumab, now called Bimzelx, is a monoclonal antibody being reviewed as treatment for adults with moderate-to-severe plaque psoriasis.
